2017-03-06,Exelixis' Cabozantinib Granted Orphan Drug Designation For The Treatment Of Hepatocellular Carcinoma
2017-03-01,Exelixis Announces Webcasts Of Investor Conference Presentations In March
2017-02-28,Exelixis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2017-02-27,Exelixis Announces Fourth Quarter And Full Year 2016 Financial Results And Provides Corporate Update
2017-02-27,Exelixis Announces Clinical Trial Collaboration With Roche To Evaluate Cabozantinib And Atezolizumab In Locally Advanced Or Metastatic Solid Tumors
2017-02-27,Exelixis And Bristol-Myers Squibb Enter Clinical Collaboration For Late-Stage Combination Trial In First-Line Renal Cell Carcinoma
2017-02-23,Incyte, Skyworks Solutions, Western Digital, Constellation Brands: 'Mad Money' Lightning Round
2017-02-23,What You Should Do if This Market Is Overvalued: Cramer's 'Mad Money' Recap (Wednesday 2/22/17)
2017-02-17,Exelixis Announces Phase 1 Trial Results For Cabozantinib In Combination With Nivolumab With Or Without Ipilimumab In Refractory Metastatic Urothelial Carcinoma And Other Genitourinary Tumors
2017-02-13,Morgan Stanley, Twitter, Tesaro: Doug Kass' Views
2017-02-07,Exelixis To Present At The Leerink Partners Global Healthcare Conference On February 15
2017-02-07,Banks, Oil, Deregulation and Your Investments: Cramer's 'Mad Money' Recap (Monday 2/6/17)
2017-02-06,Box, Nucor, Exelixis, American Airlines and more: 'Mad Money' Lightning Round
2017-02-03,Hopes for Tax Reform, Less Regulation Lift Indices
2017-02-02,Exelixis To Release Fourth Quarter And Full Year 2016 Financial Results On Monday, February 27, 2017
2017-01-31,Exelixis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2017-01-30,Exelixis And Takeda Enter Into Exclusive Licensing Agreement To Commercialize And Develop Novel Cancer Therapy Cabozantinib In Japan
2017-01-29,The Next Target in Biotech Land
2017-01-27,The Next Target in Biotech Land
2017-01-18,Home Depot, Marathon Petroleum, Huntsman: 'Mad Money' Lightning Round
2017-01-18,Investors Need a Strong Stomach as Trump Tweets: Cramer's 'Mad Money' Recap (Tuesday 1/17/17)
2017-01-10,4 Biotech Names That Could Be M&amp;A Targets
2017-01-09,Update On Dispute Between Exelixis And Genentech, A Member Of The Roche Group
2017-01-03,Exelixis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2016-12-21,Exelixis And Ipsen Amend Exclusive Licensing Agreement For The Commercialization And Development Of Cabozantinib To Include Canada
2016-12-19,The Best Biopharma CEOs of 2016 Are...
2016-12-07,Exelixis Announces Leadership Hires In Public Affairs And Business Development To Support Growth Of Company And Pipeline
2016-12-02,Look at Silver Miners and Some Names That Have Pulled Back
2016-11-30,Exelixis To Present At The BMO Prescription For Success Healthcare Conference On December 14
2016-11-29,Shark Bites: Eager Buyers Pounce on Pullback
2016-11-23,Biotech School: How to Use Kaplan-Meier Survival Curves to Become a Smarter Investor
2016-11-22,How to Be a Smarter Biotech Investor
2016-11-21,Exelixis To Present At The Piper Jaffray 28th Annual Healthcare Conference On November 29
2016-11-07,Exelixis To Present At The Stifel 2016 Healthcare Conference On November 15
2016-11-07,Exelixis Announces Presentation Of Cobimetinib Combination Therapy Data At The Society For Melanoma Research 2016 Congress That Support Genentech's Planned Phase 3 Pivotal Trials
2016-11-04,Exelixis (EXEL) Stock Gains on Q3 Results
2016-11-03,Exelixis Announces Third Quarter And Year To Date 2016 Financial Results And Provides Corporate Update
2016-10-20,Exelixis To Release Third Quarter 2016 Financial Results On Thursday, November 3, 2016
2016-10-10,Exelixis Announces Positive Results From Phase 2 CABOSUN Trial Of Cabozantinib Versus Sunitinib In Previously Untreated Advanced Renal Cell Carcinoma Presented At ESMO 2016
2016-10-07,Exelixis Announces Genentech Presentation Of Preliminary Phase 1b Results For The Combination Of Cobimetinib, Vemurafenib And Atezolizumab At ESMO 2016 Congress
2016-10-07,Exelixis Announces Phase 1 Trial Results For Cabozantinib In Combination With Nivolumab In Advanced Genitourinary Tumors
2016-10-03,Exelixis And Ipsen To Host Investor And Media Briefing To Discuss Data Presented At The ESMO 2016 Congress
2016-09-28,Exelixis (EXEL) Stock Plummets on Cancer Drug Trial Results, Leerink: Selloff Overdone
2016-09-26,Exelixis Elects Julie Anne Smith To Its Board Of Directors
2016-09-26,Exelixis Announces Collaborator Daiichi Sankyo's Initiation Of Phase 3 Clinical Development For CS-3150, A Selective Mineralocorticoid Receptor Antagonist
2016-09-23,'Mad Money' Lightning Round: Don't Sell Scripps
2016-09-22,Jim Cramer's 'Mad Money' Recap: Tune Out the Fed, Focus on What Matters
2016-09-20,Exelixis Provides Update On Timing Of Key Cabozantinib Clinical Data Presentation At The ESMO 2016 Congress
2016-09-20,2 Bullish Stock Picks and 2 Stocks to Sell Short
2016-09-14,Exelixis (EXEL) Stock Advances, EC Approves Kidney Cancer Drug
2016-09-14,European Commission Approves CABOMETYX™ (cabozantinib) Tablets For The Treatment Of Advanced Renal Cell Carcinoma Following VEGF-Targeted Therapy
2016-09-06,Exelixis Announces Outcome From First Planned Interim Analysis Of The Phase 3 CELESTIAL Trial Of Cabozantinib In Patients With Advanced Hepatocellular Carcinoma
2016-08-31,Exelixis To Present At The Morgan Stanley Global Healthcare Conference On September 13
2016-08-31,Exelixis-discovered Compounds To Be Featured In 15 Presentations At The ESMO 2016 Congress
2016-08-25,Exelixis Stock Sees Short Interest Decrease By 29.7%
2016-08-24,Exelixis Announces Redemption Of All Remaining 4.25% Convertible Senior Subordinated Notes Due 2019
2016-08-23,4 Biotech Stock Charts You Must See
2016-08-11,3 Biotech-Investing Mistakes to Avoid
2016-08-05,Trade-Ideas: Exelixis (EXEL) Is Today's "Perilous Reversal" Stock
2016-08-04,Why Exelixis (EXEL) Stock Is Soaring Today
2016-08-04,Don't Roll the Dice on Central Bank News
2016-08-03,Exelixis Announces Second Quarter And Year To Date 2016 Financial Results And Provides Corporate Update
2016-07-28,4 Tech and Biotech Stocks With Momentum to Watch
2016-07-12,Exelixis To Release Second Quarter 2016 Financial Results On Wednesday, August 3, 2016
2016-07-08,Biotech Stock Mailbag: Heron, Exelixis
2016-06-15,'Mad Money' Lightning Round: I'm Sticking With Wells Fargo
2016-06-14,Jim Cramer's 'Mad Money' Recap: We've Seen This 'Brexit' Movie Before
2016-06-09,Trade-Ideas: Exelixis (EXEL) Is Today's Strong On High Relative Volume Stock
2016-06-07,Today's Perilous Reversal Stock: Exelixis (EXEL)
2016-06-06,Exelixis (EXEL) Stock Gains on Positive Trial Results for Kidney Cancer Treatment
2016-06-06,Exelixis And Its Partner Ipsen Announce Positive Overall Survival Results From Subgroup Analyses Of Phase 3 Trial Of CABOMETYX™ (cabozantinib) Tablets In Advanced Renal Cell Carcinoma At 2016 ASCO Annual Meeting
2016-06-06,Exelixis And Its Partner Ipsen Announce Positive Overall Survival Results From Subgroup Analyses Of Phase 3 Trial Of CABOMETYX™ (cabozantinib) Tablets In Advanced Renal Cell Carcinoma At 2016 ASCO Annual Meeting
2016-06-05,Exelixis And Its Partner Ipsen Announce Phase 3 Trial Results Of CABOMETYX™ (Cabozantinib) Tablets Demonstrating Significant Overall Survival Benefit For Previously Treated Patients With Advanced Renal Cell Carcinoma Presented At ASCO
2016-06-05,Exelixis Announces Genentech Presentation Of Preliminary Phase 1B Trial Results For The Combination Of Cobimetinib And Atezolizumab At ASCO 2016 Annual Meeting
2016-05-23,Strong On High Volume: Exelixis (EXEL)
2016-05-23,Exelixis Announces Results From Randomized Phase 2 Trial CABOSUN Demonstrate Cabozantinib Significantly Improved Progression-Free Survival Versus Sunitinib In Previously Untreated Advanced Renal Cell Carcinoma
2016-05-16,Exelixis (EXEL) Showing Signs Of Perilous Reversal Today
2016-05-05,Exelixis To Present At The Bank Of America Merrill Lynch 2016 Health Care Conference On May 10
2016-05-04,Exelixis Announces First Quarter 2016 Financial Results And Provides Corporate Update
2016-04-26,Exelixis To Release First Quarter 2016 Financial Results On Wednesday, May 4, 2016
2016-04-25,CABOMETYX™ 60 Mg Tablets
2016-04-20,Exelixis-Discovered Compounds To Be Featured In 18 Presentations At 2016 ASCO Annual Meeting
2016-04-04,Exelixis (EXEL) Stock Climbs, Stifel Upgrades
2016-03-03,Exelixis To Present At Two Investor Conferences In March
2016-03-01,Exelixis (EXEL) Stock Climbs on Q4 Results
2016-02-29,Exelixis Announces Fourth Quarter And Full Year 2015 Financial Results And Provides Corporate Update
2016-02-29,Exelixis And Ipsen Enter Into Exclusive Licensing Agreement To Commercialize And Develop Novel Cancer Therapy Cabozantinib In Regions Outside The United States, Canada And Japan
2016-02-15,Exelixis To Release Fourth Quarter And Full Year 2015 Financial Results On Monday, February 29, 2016
2016-02-04,Exelixis To Present At The Leerink Partners 5th Annual Global Healthcare Conference On February 10
2016-02-01,Exelixis Kidney Cancer Survival Benefit Doesn't Address Competitive Question
2016-02-01,Exelixis Announces Positive Overall Survival Results From METEOR, The Phase 3 Pivotal Trial Of Cabozantinib In Advanced Renal Cell Carcinoma
2016-01-28,Exelixis Announces European Medicines Agency Acceptance Of Marketing Authorization Application For Cabozantinib As A Treatment For Advanced Renal Cell Carcinoma
2016-01-28,Exelixis Announces U.S. FDA Deems New Drug Application Sufficiently Complete And Grants Priority Review For Cabozantinib As A Treatment For Advanced Renal Cell Carcinoma
2016-01-20,'Mad Money' Lightning Round: Move on From Broadcom
2016-01-19,Jim Cramer's 'Mad Money' Recap: Wait for Weakness, Then Pounce
2016-01-11,Exelixis Submits Marketing Authorization Application In The European Union For Cabozantinib As A Treatment For Advanced Renal Cell Carcinoma
2016-01-04,Exelixis Announces Positive Results From Subgroup Analyses Of The METEOR Phase 3 Pivotal Trial Of Cabozantinib In Advanced Renal Cell Carcinoma To Be Presented At ASCO 2016 Genitourinary Cancers Symposium
2015-12-23,Exelixis (EXEL) Stock Spikes, Submits New Drug Application
2015-12-23,Exelixis Completes Submission Of New Drug Application For Cabozantinib For The Treatment Of Advanced Renal Cell Carcinoma
2015-11-25,Exelixis Announces European Commission Approval Of COTELLIC™ (Cobimetinib) For Use In Combination With Vemurafenib In Advanced BRAF V600 Mutation-Positive Melanoma
2015-11-21,Exelixis Announces Presentation Of Positive Overall Survival Results For COTELLIC™ In Combination With Vemurafenib In Advanced BRAF V600 Mutation-Positive Melanoma At Society For Melanoma Research 2015 International Congress
2015-11-12,Exelixis To Present At The Stifel 2015 Healthcare Conference On Tuesday, November 17
2015-11-11,Exelixis (EXEL) Stock Dropped Following Earnings Release
2015-11-10,Exelixis (EXEL) Stock Declines in After-Hours Trading on Quarterly Loss
2015-11-10,Exelixis Announces Third Quarter 2015 Financial Results And Provides Corporate Update
2015-11-10,FDA Approves COTELLIC™ (Cobimetinib) For Use In Combination With Vemurafenib To Treat Advanced Melanoma
2015-10-22,Exelixis Initiates Rolling Submission Of U.S. New Drug Application For Cabozantinib For The Treatment Of Advanced Kidney Cancer
2015-10-20,Exelixis To Release Third Quarter 2015 Financial Results On Tuesday, November 10, 2015
2015-10-06,Exelixis Announces Positive Overall Survival Results From Phase 3 Pivotal Trial Of Cobimetinib In Combination With Vemurafenib In Patients With BRAF V600 Mutation-Positive Advanced Melanoma
2015-09-30,10 Best Nasdaq Biotech Stocks in the Third Quarter
2015-09-29,4 Stocks Under $10 Making Big Moves Higher
2015-09-25,Exelixis Announces Positive Results From METEOR Phase 3 Pivotal Trial Of Cabozantinib In Advanced Renal Cell Carcinoma Presented At European Cancer Congress 2015
2015-09-25,Bristol, Exelixis Drugs Demonstrate Treatment Benefit in Kidney Cancer
2015-09-25,European CHMP Adopts Positive Opinion For Cobimetinib In Combination With Vemurafenib For The Treatment Of Advanced Melanoma
2015-09-24,Exelixis Announces Key Senior Leadership Hires In Medical Affairs, Sales, And Marketing To Support Commercialization Of Cabozantinib And Cobimetinib
2015-09-22,Exelixis To Host Investor/Analyst Webcast During European Cancer Congress 2015
2015-09-18,Biotech Stock Mailbag: Bristol, Exelixis, Lion Bio, GW Pharma
2015-09-16,'Mad Money' Lightning Round: Buy, Buy, Buy Bristol-Myers Squibb
2015-09-15,Jim Cramer's 'Mad Money' Recap: 6 Ways Markets Will Be Hit by a Rate Hike
2015-08-31,Interesting EXEL Put And Call Options For October 16th
2015-08-27,Exelixis (EXEL) Stock Climbs as Melanoma Treatment Gets Swiss Regulatory Approval
2015-08-27,Use Options For a Chance To Buy EXEL at a 58% Discount
2015-08-27,Exelixis Announces First Regulatory Approval Of Cobimetinib In Switzerland
2015-08-24,Data From METEOR Pivotal Trial Of Cabozantinib In Advanced Renal Cell Carcinoma Accepted As Late-Breaker Presentation In Presidential Session At European Cancer Congress 2015
2015-08-24,FDA Grants Breakthrough Therapy Designation To Exelixis' Cabozantinib For The Treatment Of Renal Cell Carcinoma In Patients Who Received One Prior Therapy
2015-08-21,'Mad Money' Lightning Round: I'm Staying Away From Alibaba
2015-08-20,Jim Cramer's 'Mad Money' Recap: Market Slaughters Disney, With More to Come
2015-08-11,Exelixis Announces Second Quarter 2015 Financial Results And Provides Corporate Update
2015-08-04,'Mad Money' Lightning Round: Marriott International Is a Buy
2015-08-03,Jim Cramer's 'Mad Money' Recap: Why the Oil and China News Isn't All Bad
2015-07-28,Exelixis To Release Second Quarter 2015 Financial Results On Tuesday, August 11, 2015
2015-07-27,Exelixis (EXEL) Stock Falls on Upsized Secondary Offering
2015-07-24,How to Trade 4 of the Market's Most Active Stocks
2015-07-23,Exelixis Prices Public Offering Of Common Stock
2015-07-22,Exelixis (EXEL) Stock Declines on Secondary Public Offering
2015-07-21,Exelixis Launches Proposed Public Offering Of Common Stock
2015-07-20,Exelixis Scores Much-Needed Kidney Cancer Study Win to Boost Drug Sales
2015-07-20,Exelixis Announces Positive Top-Line Results From METEOR, The Phase 3 Pivotal Trial Of Cabozantinib Versus Everolimus In Patients With Metastatic Renal Cell Carcinoma
2015-07-15,Exelixis Appoints Chris Senner As Executive Vice President And Chief Financial Officer
2015-07-13,Exelixis Announces Start Of Phase 1 Trial Of Cabozantinib In Combination With Nivolumab Or Nivolumab Plus Ipilimumab In Patients With Advanced/Metastatic Urothelial Carcinoma And Other Genitourinary Tumors
2015-07-01,10 Best Biotech Stocks in the NASDAQ
2015-07-01,Exelixis Provides Update On Genentech's Pending New Drug Application For Cobimetinib, An Exelixis-Discovered Compound
2015-06-26,First Week Of EXEL February 2016 Options Trading
2015-06-26,Biotech Stock Mailbag: Exelixis, Puma Bio
2015-06-03,Where the Money Was Made the Last 5 Years
2015-05-31,Exelixis Announces Positive Results From Phase 2 Investigator-Sponsored Trial Of Cabozantinib In RET-Rearranged Non-Small Cell Lung Cancers
2015-05-31,Exelixis Announces Positive Results From Phase 2 Trial Of Cabozantinib In Patients With EGFR Wild-Type Non-Small Cell Lung Cancer
2015-05-30,Updated Positive Results From Two Trials Of Cobimetinib In Combination With Vemurafenib For The Treatment Of Patients With Advanced Melanoma Presented At 2015 ASCO Annual Meeting
2015-05-23,'Mad Money' Lightning Round: Buy Disney, Be Careful With Exelixis
2015-05-22,Jim Cramer's 'Mad Money' Recap: Here's My Game Plan for Next Week
2015-05-19,First Week Of EXEL July 17th Options Trading
2015-05-08,Exelixis (EXEL) Stock Spikes on First Quarter Earnings Report
2015-05-04,Exelixis To Present At The Bank Of America Merrill Lynch 2015 Health Care Conference On May 12
2015-04-30,Cabozantinib And Cobimetinib To Be Featured In Fourteen Presentations At 2015 ASCO Annual Meeting
2015-04-30,Exelixis Announces First Quarter 2015 Financial Results And Provides Corporate Update
2015-04-16,Exelexis (EXEL) Is The 'Chart of the Day'
2015-04-09,Exelixis To Release First Quarter 2015 Financial Results On Thursday, April 30, 2015
2015-04-09,Exelixis (EXEL) Stock Rises Today Following FDA Fast Track Designation
2015-04-09,Exelixis' Cabozantinib Granted Fast Track Designation By FDA For Advanced Renal Cell Carcinoma
2015-03-12,Exelixis (EXEL) Highlighted As Weak On High Volume
2015-03-03,Exelixis (EXEL) In A Perilous Reversal
2015-02-26,Exelixis To Present At The Cowen And Company 35th Annual Health Care Conference On Tuesday, March 3
2015-02-24,Exelixis Announces Fourth Quarter And Full Year 2014 Financial Results And Provides Corporate Update
2015-02-19,Exelixis Announces Acceptance Of New Drug Application For Cobimetinib In Combination With Vemurafenib For Treatment Of Patients With BRAF V600 Mutation-Positive Advanced Melanoma
2015-02-11,Exelixis (EXEL) Is Today's Strong On High Volume Stock
2015-02-10,4 Biotech Stocks Under $10 Triggering Breakouts: Amarin, Exelixis and More
2015-02-02,Exelixis To Release Fourth Quarter And Full Year 2014 Financial Results On Tuesday, February 24, 2015
2015-01-29,Exelixis To Present At The Leerink Global Healthcare Conference On Wednesday, February 11
2015-01-28,Exelixis (EXEL) Flagged As Strong On High Volume
2015-01-08,Exelixis (EXEL) Is Today's Strong On High Volume Stock
2015-01-07,Exelixis And Swedish Orphan Biovitrum AB (Sobi) Extend And Restructure Distribution Agreement For COMETRIQ® For Medullary Thyroid Cancer
2014-12-15,Exelixis' Collaborator Genentech Files New Drug Application For The Combination Of Cobimetinib And Vemurafenib For The Treatment Of Patients With BRAF V600 Mutation-Positive Advanced Melanoma
2014-12-01,Future of Exelixis Cancer Drug Dims Further With Second Failed Prostate Cancer Study
2014-12-01,Exelixis Announces Results From The COMET-2 Pivotal Phase 3 Trial Of Cabozantinib In Men With Metastatic Castration-Resistant Prostate Cancer
2014-11-25,Exelixis To Present At The Piper Jaffray 26th Annual Healthcare Conference On Tuesday, December 2
2014-11-16,Exelixis Announces Positive Preliminary Data From An Investigator-Sponsored Phase 1 Trial Of XL888 And Vemurafenib
2014-11-11,Exelixis To Present At The Stifel 2014 Healthcare Conference On Tuesday, November 18
2014-11-06,Exelixis Completes Enrollment Of The METEOR Phase 3 Pivotal Trial Of Cabozantinib In Metastatic Renal Cell Carcinoma
2014-11-04,Exelixis Announces Positive Top-Line Results From A Phase 2 Trial Of Cabozantinib And Erlotinib In Patients With EGFR Wild-Type Non-Small Cell Lung Cancer
2014-11-04,Exelixis Announces Third Quarter 2014 Financial Results And Provides Corporate Update
